Shield Therapeutics PLC Investor presentation
May 02 2019 - 1:00AM
RNS Non-Regulatory
TIDMSTX
Shield Therapeutics PLC
02 May 2019
Shield Therapeutics plc
(the "Company")
Investor presentation
London, UK, 2 May 2019. Shield Therapeutics plc (LSE:STX), a
commercial stage pharmaceutical company with a focus on addressing
iron deficiency with or without anaemia via its lead product
Feraccru(R), announces that it will be presenting at the ShareSoc
Growth Company Seminar in London on Wednesday 8 May, 2019.
ShareSoc is an organisation dedicated to supporting individual
private shareholders ensuring that they have a voice and better
access to information on the companies they invest in.
The event will commence at 5.30pm at the offices of Link Asset
Services, 65 Gresham Street, London, EC2V 7NQ. At the event CFO Tim
Watts will deliver a presentation detailing the Company's strategy
followed by a Q&A session.
No new material information will be disclosed during the
event.
If you are interested in attending the event and would like
information on how to register please contact Walbrook PR at
shield@walbrookpr.com
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial
Officer
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7841
Paul McManus / Helen Cresswell 917 679
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company
delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. The Company's clear purpose is to
help its patients become people again, by enabling them to enjoy
the things that make the difference in their everyday lives. The
Group has a marketed product, Feraccru(R), for the treatment of
iron deficiency in adults which has exclusive IP rights until the
mid-2030s. Feraccru(R) is commercialised in the European Union by
Norgine BV and the US Food and Drug Administration (FDA) is
currently considering a New Drug Application (NDA), with a PDUFA
(Prescription Drug User Fee Act) date of 27(th) July 2019. For more
information please visit www.shieldtherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAABMJTMBAMBJL
(END) Dow Jones Newswires
May 02, 2019 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024